



# MetaVia

## **MetaVia to Present at the Emerging Growth Conference in December**

December 2, 2024

CAMBRIDGE, Mass., Dec. 2, 2024 /PRNewswire/ -- **MetaVia Inc.** (Nasdaq: [MTVA](#)), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company update at the Emerging Growth Conference on Wednesday, December 4, 2024 at 4:10 pm ET.

After the presentation, MetaVia management will open the floor for questions. Please submit your questions in advance to [questions@emerginggrowth.com](mailto:questions@emerginggrowth.com), or ask your questions during the event.

Please register using this [link](#) to attend the virtual conference and receive any updates that are released. To schedule a meeting with management outside of the conference, please contact Michael Miller at [mmiller@rxir.com](mailto:mmiller@rxir.com).

### **About MetaVia**

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism,

reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control.

For more information, please visit [www.metaviatx.com](http://www.metaviatx.com).

**Contacts:**

**MetaVia**

Marshall H. Woodworth

Chief Financial Officer

+1-857-299-1033

[marshall.woodworth@metaviatx.com](mailto:marshall.woodworth@metaviatx.com)

**Rx Communications Group**

Michael Miller

+1-917-633-6086

[mmiller@rxir.com](mailto:mmiller@rxir.com)

SOURCE MetaVia Inc.